Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has been given a consensus rating of "Buy" by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $11.40.

Several equities research analysts recently commented on the stock. Maxim Group upgraded shares of Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 target price on the stock in a research report on Friday, January 10th. D. Boral Capital reissued a "buy" rating and issued a $15.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a "buy" rating and a $7.00 target price for the company. Roth Capital upgraded Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 10th. Finally, HC Wainwright lowered their price objective on Reviva Pharmaceuticals from $14.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday, January 22nd.

Reviva Pharmaceuticals Trading Up 0.5 %

RVPH traded up $0.01 on Wednesday, reaching $2.08. The stock had a trading volume of 1,381,820 shares, compared to its average volume of 1,768,137. The company has a market capitalization of $69.56 million, a price-to-earnings ratio of -1.87 and a beta of -0.12. Reviva Pharmaceuticals has a fifty-two week low of $0.60 and a fifty-two week high of $4.83. The firm has a 50-day moving average of $1.86 and a 200-day moving average of $1.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in RVPH. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals by 17.9% in the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company's stock worth $401,000 after purchasing an additional 42,376 shares in the last quarter. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $36,000. EMC Capital Management increased its stake in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company's stock valued at $81,000 after acquiring an additional 26,134 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter valued at $25,000. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.